Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kassiou

Showing results (1-10 of 231) with videos related to

Pageof 24
Sort By:
Nuclear Medicine and Biology|April 29, 2022
Tracer development for PET imaging of proteinopathiesAnnukka Kallinen, Michael Kassiou
Mini Reviews in Medicinal Chemistry|November 17, 2004
Development of radioligands for in vivo imaging of GABA(A)-benzodiazepine receptorsAndrew Katsifis, Michael Kassiou
Expert Opinion on Therapeutic Patents|March 9, 2010
P2X purinergic receptor ligands: recently patented compoundsHendra Gunosewoyo, Michael Kassiou
Methods in Molecular Biology (Clifton, N.J.)|September 22, 2021
Measuring Affinity of Ligands to the Oxytocin Receptor Using Radioligand BindingEryn L Werry, Michael Kassiou
Current Pharmaceutical Design|February 1, 2012
The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidenceSamuel D Banister, Michael Kassiou
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 19, 2011
The translocator proteinAlana M Scarf, Michael Kassiou
Expert Opinion on Therapeutic Patents|September 15, 2017
A patent review of oxytocin receptor antagonists 2013-2017Timothy A Katte, Michael Kassiou
European Journal of Drug Metabolism and Pharmacokinetics|May 21, 2004
The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animalsPeter Roselt, Steven Meikle, Michael Kassiou
Current Medicinal Chemistry|July 18, 2006
Development of ligands for the peripheral benzodiazepine receptorMichelle L James, Silvia Selleri, Michael Kassiou
International Journal of Molecular Sciences|November 13, 2021
Senolytics: A Novel Strategy for Neuroprotection in ALS?Alexandra Maximova, Eryn L Werry, Michael Kassiou
Pageof 24

Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
Nuclear Medicine and Biology|April 29, 2022
Tracer development for PET imaging of proteinopathiesAnnukka Kallinen, Michael Kassiou
Mini Reviews in Medicinal Chemistry|November 17, 2004
Development of radioligands for in vivo imaging of GABA(A)-benzodiazepine receptorsAndrew Katsifis, Michael Kassiou
Expert Opinion on Therapeutic Patents|March 9, 2010
P2X purinergic receptor ligands: recently patented compoundsHendra Gunosewoyo, Michael Kassiou
Methods in Molecular Biology (Clifton, N.J.)|September 22, 2021
Measuring Affinity of Ligands to the Oxytocin Receptor Using Radioligand BindingEryn L Werry, Michael Kassiou
Current Pharmaceutical Design|February 1, 2012
The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidenceSamuel D Banister, Michael Kassiou
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 19, 2011
The translocator proteinAlana M Scarf, Michael Kassiou
Expert Opinion on Therapeutic Patents|September 15, 2017
A patent review of oxytocin receptor antagonists 2013-2017Timothy A Katte, Michael Kassiou
European Journal of Drug Metabolism and Pharmacokinetics|May 21, 2004
The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animalsPeter Roselt, Steven Meikle, Michael Kassiou
Current Medicinal Chemistry|July 18, 2006
Development of ligands for the peripheral benzodiazepine receptorMichelle L James, Silvia Selleri, Michael Kassiou
International Journal of Molecular Sciences|November 13, 2021
Senolytics: A Novel Strategy for Neuroprotection in ALS?Alexandra Maximova, Eryn L Werry, Michael Kassiou
Pageof 24